- Category
- Micro (2021-22)
- Udyam number
- UDYAM-BR-26-0043125

Docnoll Medsol Private Limited
About Docnoll Medsol Private Limited
Data last updated:
Docnoll Medsol Private Limited is a private limited company based in Patna, Bihar, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 February 2022.
The company is registered with the Registrar of Companies (ROC), Patna, under CIN U85300BR2022PTC056585. Its GSTIN is 10AAJCD1006D1ZN (Bihar).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹4 Lakh. It is led by directors including Pawan Kumar and Prem Pankaj.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Patna, Bihar.
Docnoll Medsol Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-BR-26-0043125).
Company details
Recognitions & Rankings of Docnoll Medsol
Contact details
Docnoll Medsol Private Limited's registered office is in Patna, Bihar.
- Registered AddressPrem Pankaj S/O Rajendra Prasad 470 Office No 205 Kauslya State Block A Dakbunglow R, Oad, Patna, Bihar, India – 800001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Docnoll Medsol Private Limited
FY 2024 filings availableFinancial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | |||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | |||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | |||
| Net Profit Margin | |||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Docnoll Medsol Private Limited, buy the company report.
Board of directors of Docnoll Medsol Private Limited
Docnoll Medsol has 4 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pawan Kumar | Director | 22 Feb 2022 | 4 Years 9 Months | Current |
| Prem Pankaj Also directs: Rajshree Agroproduct Private Limited | Director | 22 Feb 2022 | 4 Years 9 Months | Current |
| Nishant Kumar Also directs: Ansas Trade Private Limited | Director | 22 Feb 2022 | 4 Years 9 Months | Current |
| Anupriya Kumari | Director | 22 Feb 2022 | 4 Years 9 Months | Current |
Legal cases
No court or tribunal cases involving Docnoll Medsol Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Docnoll Medsol Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Docnoll Medsol has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAJCD1006D1ZN | Bihar | Active | 10 Jun 2022 |
To see the full GST registrations and return filing status of Docnoll Medsol Private Limited, buy the company report.
Recent activity
Docnoll Medsol Private Limited has 4 board changes on record since 2022: 4 appointments. The latest: Anupriya Kumari was appointed as Director on 22 Feb 2022.
Frequently asked questions
Docnoll Medsol is an active private limited company based in Patna, Bihar, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 February 2022 (4+ years old) and is registered under CIN U85300BR2022PTC056585.
Docnoll Medsol has 4 current directors:
- Pawan Kumar - Director
- Prem Pankaj - Director
- Nishant Kumar - Director
- Anupriya Kumari - Director
The latest financial statements of Docnoll Medsol on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Docnoll Medsol is 10AAJCD1006D1ZN, registered in Bihar.
The CIN (Corporate Identification Number) of Docnoll Medsol is U85300BR2022PTC056585. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Docnoll Medsol was incorporated on 22 February 2022, making it 4+ years old. It is registered with the Registrar of Companies, Patna.
Anupriya Kumari was appointed as Director on 22 Feb 2022. Nishant Kumar was appointed as Director on 22 Feb 2022. Pawan Kumar was appointed as Director on 22 Feb 2022. Docnoll Medsol has 4 board changes on record in total.
Yes, Docnoll Medsol is registered as a micro enterprise under Udyam registration (number: UDYAM-BR-26-0043125).
The registered office of Docnoll Medsol is at Prem Pankaj SO Rajendra Prasad 470 Office No 205 Kauslya State Block A Dakbunglow R, Oad, Patna, Bihar, India – 800001.
Docnoll Medsol operates in the pharma industry, in the drug formulation and development segment.

